#Sweden #Stockholm #SciBase #European Patent #epithelial skin barrier

SciBase Strengthens Its Intellectual Property Portfolio

In a significant advancement for dermatological technology, SciBase Holding AB, publicly traded under the ticker symbol "SCIB" in Sweden, has announced the acquisition of a new European patent titled "Medical Devices for Analyzing Epithelial Barrier Function" (EP3876835B1). This patent enhances SciBase's already extensive intellectual property portfolio, reinforcing its strategic commitment to innovating in the field of dermatology through AI-based diagnostic solutions.

Expanding Horizons

Founded upon over two decades of research from the esteemed Karolinska Institute in Stockholm, SciBase is at the forefront of skin disorder diagnostics. The newly granted patent aligns perfectly with the company's goal of developing innovative medical and research solutions that provide enhanced understanding of the epithelial skin barrier, a critical component of skin health. According to Pia Renaudin, CEO of SciBase, safeguarding their innovations through patents is essential for their growth strategy. Renaudin expressed gratitude to Professor Cezmi Akdis for his significant contributions throughout the formulation and data collection stages of this patent application.

Key Features of the Patent

The granted patent covers several important capabilities, specifically:

• - In Vivo Assessment: Evaluating epithelial barrier function in living subjects using electrical impedance measurements, allowing for real-time insights.
• - Drug Effect Analysis: Determining the effects of medications on patients, particularly regarding the epithelial skin barrier's response to treatment in vivo.
• - Environmental Stability: Employing a method of analysis that remains stable despite environmental influences, enhancing the reliability of results.

This patent represents a commitment to pioneering advancements in dermatological diagnostics, helping to detect and monitor skin conditions more effectively than ever before. The patent remains valid until 2039 within the European area.

The Role of AI in Dermatology

As a medical technology company focusing on early detection and prevention in dermatology, SciBase integrates artificial intelligence into its diagnostic solutions to improve accuracy and efficacy. Their flagship product, Nevisense, provides a unique point-of-care diagnostic platform that combines AI technology with advanced electrical impedance spectroscopy (EIS). Through these innovations, SciBase aims to enhance proactive management of skin health, minimize patient suffering, and reduce healthcare costs dramatically.

Future Outlook

With the acquisition of this patent, SciBase not only cements its place as a leader in dermatological technology but also opens the door for various potential applications in broader healthcare contexts. The company anticipates that the insights gained from understanding the epithelial skin barrier could lead to significant advancements in treating skin disorders, thereby positively impacting patient outcomes.

As noted by Renaudin, the potential for growth in this field is substantial, and securing this patent strengthens the company’s long-term position in the market. With ongoing collaborations and commitment to research, SciBase is poised to be at the cutting edge of dermatological innovation for years to come.

Conclusion

In conclusion, the granting of this European patent marks an exciting chapter for SciBase and the medical community. As the company continues to develop groundbreaking technologies that enhance understanding and treatment of skin conditions, patients can look forward to improved health outcomes driven by timely diagnoses and interventions. The advancements outlined in this patent will undoubtedly help propel the company further towards its mission of improving lives through innovative dermatological solutions, ensuring that the importance of skin health remains a priority in medicine today.

For more information, please visit SciBase's website.
For inquiries or further details, Pia Renaudin can be contacted at +46732069802 or via email at [email protected].